

Amendments to the Specification:

Please replace the first paragraph on page 2 with the following amended paragraph:

Placental bikunin, a novel human serine protease inhibitor containing two Kunitz-like domains, has been cloned and expressed (Delaria et al., J. Biol. Chem. 272(18):12209-12214, 1997). Characterization studies showed that truncated placental bikunin is a potent inhibitor of kallikrein and plasmin. The sequence of truncated placental bikunin is shown in Figure 2. The protease inhibitory function of bikunin suggests that placental bikunin has important therapeutic application for the treatment of a variety of disorders including prevention of disseminated intravascular coagulation, reduction of blood loss during surgery, reduction of brain edema following vascular injury, and blockage of tumor growth and invasiveness (Marlor et al., J. Biol. Chem. 272(18):12202-12208, 1997). An unexpected observation was made recently that placental bikunin was able to increase airway surface liquid osmolarity and mucociliary transport in animal models (U.S. Patent Application No. 09/441,966 09/218,913, filed ~~November 17, 1999~~ December 22, 1998, entitled "Method for Accelerating the Rate of Mucociliary Clearance"). Thus there is a need to produce placental bikunin in large quantities.